ScoreWhy is Jiangsu Aidea Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 0.38%
- The company has been able to generate a Return on Capital Employed (avg) of 0.38% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of 17.13% and Operating profit at -294.98% over the last 5 years
3
The company has declared positive results in Mar'2025 after 5 consecutive negative quarters
- OPERATING CASH FLOW(Y) Highest at CNY 75.64 MM
- PRE-TAX PROFIT(Q) At CNY 22.75 MM has Grown at 150.65%
- RAW MATERIAL COST(Y) Fallen by -80.72% (YoY)
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 37.22%, its profits have risen by 26.9%
5
Market Beating Performance
- The stock has generated a return of 37.22% in the last 1 year, much higher than market (China Shanghai Composite) returns of 14.77%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Jiangsu Aidea Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Jiangsu Aidea Pharmaceutical Co., Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Jiangsu Aidea Pharmaceutical Co., Ltd.
-100.0%
-0.05
55.54%
China Shanghai Composite
15.19%
1.01
14.58%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
17.13%
EBIT Growth (5y)
-294.98%
EBIT to Interest (avg)
-26.07
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.06
Sales to Capital Employed (avg)
0.27
Tax Ratio
15.76%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.38%
ROE (avg)
0.68%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.17
EV to EBIT
-35.92
EV to EBITDA
-115.88
EV to Capital Employed
3.00
EV to Sales
5.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8.35%
ROE (Latest)
-8.32%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend27What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 75.64 MM
PRE-TAX PROFIT(Q)
At CNY 22.75 MM has Grown at 150.65%
RAW MATERIAL COST(Y)
Fallen by -80.72% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 2.39%
NET SALES(Q)
Highest at CNY 195.33 MM
OPERATING PROFIT(Q)
Highest at CNY 24.18 MM
OPERATING PROFIT MARGIN(Q)
Highest at 12.38 %
NET PROFIT(Q)
Highest at CNY 8.04 MM
EPS(Q)
Highest at CNY 0.04
-10What is not working for the Company
INTEREST(HY)
At CNY 8.48 MM has Grown at 13.76%
ROCE(HY)
Lowest at -10.62%
Here's what is working for Jiangsu Aidea Pharmaceutical Co., Ltd.
Net Sales
At CNY 195.33 MM has Grown at 89.55%
over average net sales of the previous four periods of CNY 103.05 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (CNY MM)
Pre-Tax Profit
At CNY 22.75 MM has Grown at 150.65%
over average net sales of the previous four periods of CNY -44.91 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 8.04 MM has Grown at 121.25%
over average net sales of the previous four periods of CNY -37.83 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Operating Cash Flow
Highest at CNY 75.64 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Net Sales
Highest at CNY 195.33 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Operating Profit
Highest at CNY 24.18 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Operating Profit Margin
Highest at 12.38 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at CNY 22.75 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Net Profit
Highest at CNY 8.04 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
EPS
Highest at CNY 0.04
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Debtors Turnover Ratio
Highest at 2.39%
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -80.72% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Jiangsu Aidea Pharmaceutical Co., Ltd.
Interest
At CNY 8.48 MM has Grown at 13.76%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
